louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03166657: Office Hysteroscopy in Secondary Infertility After Cesarean Section
Official title: Role of Office Hysteroscopy in Cases of Secondary Infertility After Cesarean Section
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility, Female
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-05-25
Enrollment: 56
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: This study will include all secondary infertile cases after cesarean section who presented to infertility clinic at Women health Hospital, Assiut University

Brief summary: All women with history of secondary infertility after caesarean section will be subjected to office hysteroscopy according to Royal college of obstetrics and gynecology guidelines to diagnose any subtle uterine abnormalities not detected by conventional means.

Hysteroscopic examination will be done during the proliferation phase of the menstrual cycle.

The hysteroscopic evaluation will include assessment of the cervical canal, intrauterine lesions, the endometrium and the uterotubal junction. .

If hysteroscopy reveal a lesion, its type, size, location will be recorded. Transvaginal ultrasound will be done after the procedure to detect fluid in the douglas pouch to confirm patent tubes.

Asses the uterine scar in details.


Eligibility criteria: Inclusion Criteria:

* Patients with secondary infertility more than 2 years after cesarean section.
* Normal semen analysis
* Normal hysterosalpingography or laparoscopy within 1year
* Evidence of ovulation by transvaginal ultrasound

Exclusion Criteria:

* • Cases with abnormal semen parameters.

  * Patients with abnormal hysterosalpingography.
  * Patients with anovulation.
  * Hormonal disturbances; high level of prolactin, thyroid hormone disturbances, very high or very low follicular stimulating hormone and luteinizing hormone
  * Patients known to be epileptic or with history of fits.
  * Cardiac patients ( valve diseases, ischemic, arrhythmic)

Primary outcomes:
measure: percentage of patients with abnormal scar findings in hysteroscopy
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Women Health Hospital
Study officials:
References:
citation: Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod. 2007 Jun;22(6):1506-12. doi: 10.1093/humrep/dem046. Epub 2007 Mar 21.
citation: Collins JA, Crosignani PG. Unexplained infertility: a review of diagnosis, prognosis, treatment efficacy and management. Int J Gynaecol Obstet. 1992 Dec;39(4):267-75. doi: 10.1016/0020-7292(92)90257-j.
Clinical trial NCT06525857: Observing Physiological Changes in Patients With Long-term Oxygen Therapy
Official title: Observing Physiological Changes in Patients With Long-term Oxygen Therapy Via Optical and Accelerometry Signals
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Chronic Respiratory Disease
Lead sponsor: Insel Gruppe AG, University Hospital Bern
Sponsor class: OTHER
First posted: 2024-07-29
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with a respiratory disease and newly prescribed LTOT

Brief summary: In this project, the investigators aim to assess changes of physiological parameters obtained non-invasively through PPG and accelerometry signals between before and during LTOT (long-term oxygen therapy) and investigate if those changes are different in patients with worsening frailty and/or improving quality of life.

For this, they will record optical (PPG) and accelerometry data via a datalogger on 40 patients undergoing LTOT and assess the PPG-derived physiological signals.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18-year-old, and
* Chronic respiratory disease including a) chronic obstructive pulmonary disease, b) interstitial lung disease, c) pulmonary hypertension, d) bronchiectasis, and
* Prescribed new LTOT due to a chronic respiratory disease with resting and/or exertional hypoxemia, and
* Able to speak/read/understand German or French, and
* Willing and able to understand and provide signed informed consent

Exclusion Criteria:

* Pregnant or lactating women, or
* Inability to follow the procedures/instructions of the study (e.g. due to language, psychological disorders, dementia, etc.), or
* Patients having a subordination link to the investigators, or
* Patients with isolated nocturnal oxygen therapy or LTOT prescription for a heart disease, sleep associated breathing disorder, neuromuscular disease or lung cancer, or
* Known participation in another human research project (ClinO/HRO) that may affect the objectives of this study.

Primary outcomes:
measure: Heart rate changes from before and during LTOT
timeFrame: From 1 week before start of LTOT to 1 month after start of LTOT
measure: Respiratory rate changes from before and during LTOT
timeFrame: From 1 week before start of LTOT to 1 month after start of LTOT
measure: SpO2 changes from before and during LTOT
timeFrame: From 1 week before start of LTOT to 1 month after start of LTOT
Secondary outcomes:
Other outcomes:
Locations:
city: Bern
country: Switzerland
facility: Inselspital, Bern University Hospital
Study officials:
affiliation: Universitätsklinik für Pneumologie, Allergologie und klinische Immunologie, Inselspital Bern
name: Sabina Guler, PD Dr. med.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01987557: Amplitude and Rate of Intrinsic Feedback During Treadmill Training for Parkinson's Disease
Official title: The Therapeutic Contributions of Somatosensory Feedback During Exercise in Parkinson's Disease; A Randomized, Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Parkinson's Disease
Treadmill
Keywords: treadmill
parkinson's
proprioception
cadence
step length
intrinsic feedback
Lead sponsor: Wilfrid Laurier University
Sponsor class: OTHER
First posted: 2013-11-19
Enrollment: 48
Sex: ALL
Minimum age (years): 40
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Treadmill training has been shown to be beneficial for reducing motor symptoms of Parkinson's disease (PD). The mechanisms for the therapeutic effects of treadmill training remain unknown. However, specific types of intrinsic feedback generated from muscle spindles (detect changes in length of muscle) and golgi tendon organs (detect muscle force) seem to be an important factor for achieving the reductions in motor scores. This study will compare a treadmill program that generates a high rate of intrinsic feedback to a treadmill program focused on generating a high magnitude of intrinsic feedback.


Eligibility criteria: Inclusion Criteria:

* diagnosis of Parkinson's disease
* must be able to walk unassisted for 10 metres

Exclusion Criteria:

* cardiovascular disease/history of stroke
* Dementia
* lower body injury that would be worsened by repetitive walking

Primary outcomes:
measure: Motor Section of the Unified Parkinson's Disease Rating Scale (UPDRS-III)
timeFrame: Pre assessments are conducted in the week prior to the treadmill program. Post are conducted during the week immediately following the program. Changes after the 6 week treadmill program are being examined
Secondary outcomes:
measure: Spatiotemporal Aspects of Gait
timeFrame: pre test occurs within the week prior to the start of the treadmill training program. Post testing will occur during the week immediately following the 6 week treadmill training program.
measure: Static Posturography (Balance/Postural Control)
timeFrame: pre test occurs within the week prior to the start of the treadmill training program. Post testing will occur during the week immediately following the 6 week treadmill training program.
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05987657: Assessment of Two Methods for Progesterone Dosage During IVF
Official title: Comparison of Two Methods to Assess Progesterone Concentration in Patient During IVF Protocol on Triggering Day: Salivary Versus Blood Test
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Keywords: Progesterone concentration
salivary test
In vitro fertilization
infertility
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2023-08-14
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 43
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Nowadays, 1/7 couple consult because of infertility and some of them will need in vitro fertilization +/- intracytoplasmic sperm injection (IVF+/- ICSI). The IVF process includes a 14 days stimulation with FSH +/- LH in an agonist or antagonist protocol. The monitoring consists of regular ultrasound scan and blood sample. During the stimulation protocol many test have been proposed to predict the success of IVF. However, progesterone dosage on triggering day seems to be the only relevant exam. Indeed, when the progesterone blood concentration is low, the pregnancy rate is decreased. The only way to obtain progesterone concentration is a blood sample. The IVF journey is known to be stressful with many injections. Therefore, the salivary dosage appear to be more patient friendly. This kind of dosage has already been studied yet never use in routine because of a lack of repeatability. The laboratory of Lyon has developed a new technique to overcome this issue by using a liquid chromatography-mass spectrometry.

The aim of this work is as a first step to assess the repeatability, reliability and precision of salivary dosage on triggering day for IVF patient compared to blood concentration of progesterone.


Eligibility criteria: Inclusion Criteria:

* Adult patients between 18 and under 43 years old
* in the course of IVF more or less ICSI of the PMA service of the HFME with transfer of fresh embryo
* Signature of an express consent
* Understanding the French language, both oral and written.
* Affiliated to a social security scheme

Exclusion Criteria:

* Persons deprived of their liberty by a judicial or administrative decision
* Persons subject to psychiatric care
* Persons admitted to a health or social establishment for purposes other than research
* Participants in another study that could impact the results of the present study, in particular those related to the level of progesterone.
* Adults subject to a legal protection measure (guardianship, curatorship)

Primary outcomes:
measure: Reliability of salivary dosage of progesterone compared to blood sample.
timeFrame: At the inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Bron
country: France
facility: Hospital Femme Mère Enfant
state: Rhône
Study officials:
References:
Clinical trial NCT02706457: Post Intensive Care Syndrome
Official title: Do Improvements in Functionality on the ICU Give a Reduction of Post Intensive Care Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Post Intensive Care Syndrome
Barthel Index
Keywords: intensive care
functionality
Lead sponsor: Frisius Medisch Centrum
Sponsor class: OTHER
First posted: 2016-03-11
Enrollment: 849
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients treated in Intensive Care for minimal 48 hours, during the years 2012 - 2014

Brief summary: Barthel Index and demographic variables of patients were collected to investigate the question whether the improvements of the functionality improves the Barthel Index over the years.

Detailed description: idem

Eligibility criteria: Inclusion Criteria:

* 18 years and older
* length of stay longer than 48 hours

Exclusion Criteria:

* no exclusion criteria if inclusion is correct

Primary outcomes:
measure: Difference in Barthel Index
timeFrame: from januari 2012 until decembre 2014
Secondary outcomes:
measure: Relation between Barthel Index and length of stay in ICU
timeFrame: from januari 2012 until decembre 2014
Other outcomes:
Locations:
city: Leeuwarden
country: Netherlands
facility: Medical Center Leeuwarden
Study officials:
affiliation: MCL
name: Matty Koopmans, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00194857: Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin
Official title: A Randomized Clinical Trial Comparing Two Management Strategies for Treatment of Neutropenia and Anemia Associated With Pegylated Interferon Plus Ribavirin Treatment of Compensated Chronic Hepatitis C in Adult Subjects Infected With HIV.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Anemia
Neutropenia
Hepatitis C Virus
HIV Infections
Keywords: anemia
dose reduction
neutropenia
hepatitis C virus
human immunodeficiency virus
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
Collaborators: name: Schering-Plough
First posted: 2005-09-19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to test two separate strategies for treatment of anemia (low hemoglobin) and neutropenia (low white blood cells) in HIV/HCV coinfected patients who are being treated with pegylated interferon and ribavirin.

Detailed description: This is a multi-center, randomized, open-labeled trial in subjects co-infected with hepatitis C (HCV) and human immunodeficiency virus type 1 (HIV-1) who are naïve to anti-HCV therapy. Subjects will receive PEG interferon alfa-2b (PEG-IFN) 1.5 mcg/kg/week administered once weekly plus ribavirin (RBV) 13 + 2 mg/kg/day. The goal of this study is to evaluate two different treatment options for anemia and neutropenia associated with the initiation of pegylated interferon and ribavirin. This will result in completion of therapy, and possibly a better viral sustained response.

Eligibility criteria: Inclusion Criteria:

* hemoglobin \> 11
* absolute neutrophil count \>1,200
* naive to peg interferon and ribavirin

Exclusion Criteria:

* Prior treatment for hepatitis C
* Pregnant or nursing

Primary outcomes:
measure: change in hemoglobin
measure: change in absolute neutrophil count
Secondary outcomes:
measure: HCV RNA
measure: depression
measure: fatigue
Other outcomes:
Locations:
city: New York
country: United States
facility: Weill Medical College of Cornell University
state: New York
Study officials:
affiliation: Weill Medical College of Cornell University
name: Andrew Talal, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Talal AH, Liu RC, Zeremski M, Dimova R, Dove L, Pearce D, Hassanein T, Doonquah L, Aboulafia D, Rodriguez J, Bonilla H, Galpin J, Aberg JA, Johnston B, Glesby MJ, Jacobson IM. Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin. J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):261-8. doi: 10.1097/QAI.0b013e3182324af9.
Clinical trial NCT04057157: Post-market Assessment of Biodesign Dural Repair Grafts
Official title: Post-market Clinical Data Collection Plan for the Biodesign® Dural and Duraplasty Grafts
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cerebrospinal Fluid Leak
Keywords: dura mater repair
cerebrospinal fluid leak
CSF leak
Biodesign® Dural Repair Graft
Biodesign® Duraplasty Repair Graft
Lead sponsor: Cook Group Incorporated
Sponsor class: INDUSTRY
First posted: 2019-08-15
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who have had dura mater repair using a Biodesign Dural or Duraplasty Graft.

Brief summary: The purpose of this clinical study is to gather post-market clinical evidence on the use of the Biodesign® Dural and Duraplasty Grafts when used as a dura substitute of the dura mater.


Eligibility criteria: Inclusion Criteria:

1. Planned use of the Biodesign Dural or Duraplasty Graft.

Exclusion Criteria:

1. Age \<18 years
2. Unable or unwilling to provide informed consent
3. Life expectancy \<6 months

Primary outcomes:
measure: Percentage of patients without clinically relevant cerebrospinal fluid (CSF) leakage
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama Birmingham Hospital
state: Alabama
city: Toronto
country: Canada
facility: Toronto Western Hospital
state: Ontario
city: Bologna
country: Italy
facility: Ospedale Bellaria-Bolonga
Study officials:
References:
Clinical trial NCT00588757: Comparison Between Two Optional IVC Filters Regardind Ease of Use,Complications and Outcome
Official title: Prospective Comparison Between OptEase and Gunter-Tulip
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Trauma
Deep Vein Thrombosis
Keywords: IVC filters
Trauma
Dwell time
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2008-01-09
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: OptEase filters are easier to retrieve but the dwell time is shorter than the Gunter filters. There are more thrombi on the OptEase than on the Gunter at the time of retrieval. OptEase filter has a better infitration capabillity due to its diamond shape. OptEase filters will hjave more IVC occlusions as a complication.

Detailed description: We will isert the two filters blindly. We will follow the patients clinically and if needed we will add imaging exams. We will try to retrieve most filters.

Eligibility criteria: Inclusion Criteria:

* All patients referred for filter insertion

Exclusion Criteria:

* Young age (\<18 years)

Primary outcomes:
measure: comparing the two filters
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Tel hashomer
country: Israel
facility: Sheba medical center
Study officials:
affiliation: Sheba Medical Center
name: Uri Rimon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06163157: Investigation of the Effectiveness of Connective Tissue Massage in Individuals With Erectile Dysfunction Symptoms
Official title: Investigation of the Effectiveness of Connective Tissue Massage in Individuals With Erectile Dysfunction Symptoms
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Erectile Dysfunction
Keywords: Erectile dysfunction
Connective tissue massage
Lead sponsor: Bitlis Eren University
Sponsor class: OTHER
First posted: 2023-12-08
Enrollment: 30
Sex: MALE
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study, it is planned to investigate the effect of connective tissue massage on symptom severity, autonomic functions, psychological state and quality of life in individuals with erectile dysfunction symptoms.

Detailed description: The most common sexual dysfunctions in men include erectile dysfunction and premature ejaculation. Erectile dysfunction (ED) is defined as the inability to achieve and maintain the penile erection necessary for sexual intercourse for at least 6 months.The prevalence of ED generally varies between 37.2%-48.6%.

There are various treatment methods used in individuals with ED symptoms. While urologists use oral phosphodiesterase-5 inhibitor drugs (such as sildenafil and vardenafil) as the first step, intracavernosal papaverine or alprostadil injections and vacuum devices may be preferred afterwards. When these treatments are inadequate, penile prostheses can be used. In addition, various physiotherapy techniques such as pelvic floor muscle training, electrical stimulation, massage and aerobic exercises are also recommended for these individuals.

Eligibility criteria: Inclusion Criteria:

* Male subjects aged 20-65 years with ED complaints for at least 6 months will be included in the study. In addition, sexually active individuals will be included in the study

Exclusion Criteria:

* Patients with diabetes and renal diseases, uncontrolled hypertension, priapism, pacemaker users, history of psychiatric or psychological illness, skin lesions/ulcer in the penis or lumbosacral region, and patients who are unable to cooperate will be excluded.

Primary outcomes:
measure: The International Index of Erectile Function (IIEF-5)
timeFrame: Change from baseline at 4 weeks
measure: Composite Autonomic Symptom Score (COMPASS 31)
timeFrame: Change from baseline at 4 weeks
Secondary outcomes:
measure: Depression Anxiety Stress Scale (DASS-21)
timeFrame: Change from baseline at 4 weeks
measure: Quality of Life Questionnaire (SF-36)
timeFrame: Change from baseline at 4 weeks
Other outcomes:
Locations:
city: Bitlis
country: Turkey
facility: Bitlis Eren University
Study officials:
References: